13th August 2024
British National Formulary
This update contains 5 significant changes, 3 dose changes, and…
Psychotropic Drug Directory supports the optimal and rational use of medicines, to improve the quality of life for people with mental health needs.
Close
Close
Contact our team to see how our services can directly help you.
Close
Access our useful resources today to help your organisation realise the benefits of subscribing to Psychotropic Drug Directory through MedicinesComplete. Including patient case studies covering everyday clinical scenarios, and an on-demand webinar showing how to navigate independent information, advice, and commentary on psychotropic drugs.
Close
Register for this live webinar to learn how to use Psychotropic Drug Directory through MedicinesComplete in clinical practice.
Close
Learn more about how we're celebrating two decades of MedicinesComplete.
Close
Practical and evidence based, British National Formulary (BNF) is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes.
An integral part of the UK’s healthcare infrastructure and relied on by health professionals who prescribe, dispense, and administer medicines globally. Reflecting current best practice as well as legal and professional guidelines relating to the uses of medicines, BNF supports safe and effective decision-making at the point of care.
Our knowledge products are regularly updated online through MedicinesComplete
13th August 2024
This update contains 5 significant changes, 3 dose changes, and…
13th August 2024
This update contains 5 significant changes, 3 dose changes, and 3 new monographs.
Significant Changes:
•Immunisation schedule: updated guidance for immunisation against influenza.
•Influenza vaccine: updated guidance for immunisation.
•Medical emergencies in the community: updated guidance on the use of salbutamol in the management of acute asthma.
•Migraine: updated guidance to include atogepant for migraine prophylaxis.
•Topical corticosteroids: introduction of new labelling and a reminder of the possibility of severe side effects, including Topical Steroid Withdrawal Reactions [MHRA/CHM advice] (advice in relevant monographs; see example in betamethasone).
Dose Changes:
•Levomepromazine [update to palliative care indications and dosing].
•Midazolam [update to palliative care indications and dosing].
•Salbutamol [update to dosing for asthma; prophylaxis of allergen-or-exercise-induced bronchospasm; other conditions associated with reversible airways obstruction (adults only); and exacerbation of reversible airways obstruction (children only)].
New Monographs:
•Dzuveo® [sufentanil].
•Exblifep® [cefepime with enmetazobactam].
•Rystiggo® [rozanolixizumab].
9th July 2024
This update contains 8 significant changes, 2 new monographs and…
9th July 2024
This update contains 8 significant changes, 2 new monographs and 1 deleted monograph.
Significant Changes:
New Monographs:
Deleted Monographs:
11th June 2024
This update contains 10 significant changes, 9 dose changes, 5…
11th June 2024
This update contains 10 significant changes, 9 dose changes, 5 new monographs and 3 deleted monographs.
Significant Changes:
Dose Changes:
New Monographs:
Deleted Monographs:
14th May 2024
This update contains 8 significant changes, 5 dose changes, 5…
14th May 2024
This update contains 8 significant changes, 5 dose changes, 5 new monographs, 2 new preparations and 2 deleted monographs.
Significant Changes:
Dose Changes:
New Monographs:
New Preparations: Kinpeygo® [budesonide]; Otinova® [aluminium acetate].
Deleted Monographs: Chloroquine with proguanil; Proguanil hydrochloride.
9th April 2024
This update contains 6 significant changes, 5 new monographs, 3…
9th April 2024
This update contains 6 significant changes, 5 new monographs, 3 new preparations, 1 deleted monograph and 2 deleted preparations.
Significant Changes:
New Monographs:
New Preparations: Emylif® orodispersible film [riluzole]; Etacortilen® eye drops [dexamethasone]; Mounjaro KwikPen® [tirzepatide].
Deleted Monographs: Benzoin tincture, compound.
Deleted Preparations: Hibitane® Plus 5% concentrate solution [chlorhexidine]; Zofran® suppository [ondansetron].
12th March 2024
This update contains 5 significant changes, 1 dose change, 4…
12th March 2024
This update contains 5 significant changes, 1 dose change, 4 new monographs and 2 deleted monographs.
Significant Changes:
Aripiprazole (Abilify® and generic brands): risk of pathological gambling [MHRA/CHM advice].
Empagliflozin: update to advice on use in renal impairment, including new indication for chronic kidney disease.
Quinolones: must now only be prescribed when other commonly recommended antibiotics are inappropriate [MHRA/CHM advice] (see example in ciprofloxacin).
Type 2 diabetes: updated guidance for management.
Vitamin B12: advise patients with known cobalt allergy to be vigilant for sensitivity reactions [MHRA/CHM advice] (advice in cyanocobalamin, hydroxocobalamin; see example in hydroxocobalamin).
Dose Changes:
New Monographs:
Deleted Monographs: Cinchocaine hydrochloride with fluocortolone caproate and fluocortolone pivalate; Simvastatin with fenofibrate.
Access British National Formulary through MedicinesComplete today.
Contact us now for pricing and access information.
BNF content is copyright © BMJ Publishing Group Ltd and Royal Pharmaceutical Society of Great Britain. BNFC content is copyright © BMJ Publishing Group Ltd, Royal Pharmaceutical Society of Great Britain, RCPCH Publications. All rights reserved.
A significant investment from National Institute for Health and Care Excellence (NICE) ensures that, with our partners BMJ Group and Royal College of Paediatrics and Child Health, we support NHS health professionals in the UK with unlimited access to BNF content online through MedicinesComplete, via the BNF + BNFC app.
$850.00
Info$99.00
Info$79.00
InfoSee all our printed publications in the Shop.
Instant online access to our essential knowledge 24/7
The Royal Pharmaceutical Society’s official journal
Trusted knowledge and revision for tomorrow’s pharmacists
High impact research in pharmaceutical sciences